Minocycline with Aspirin: An Approach to Attenuate Diabetic Nephropathy in Rats

Figures & data

Table 1. Effects of 4-week treatment with MINO, ASP, and MINO in combination with ASP on renal function tests

Groups	NORMO	DB + DW	DB + ASP	DB + MINO	DB + MINO + ASP	DB + 0.5% CMC
Plasma glucose (mg/dL)	113 ± 7.16	421 ± 14.65	412 ± 20.77	421 ± 20.80	409 ± 16.83	424 ± 28.21
Body weight (g)	262.4 ± 14.10	217.4 ± 7.96	211.2 ± 11.03	215 ± 9.41	214.8 ± 13.24	210.2 ± 12.26
Food intake (g)	32.2 ± 5.2	65.6 ± 6.7	63.2 ± 7.5	64.6 ± 4.5	62 ± 5.1	62.6 ± 5.5
Water intake (mL)	35.4 ± 4.9	123.6 ± 7.3	108.2 ± 8.1	99.4 ± 9.1*	81.8 ± 6.1**	121.4 ± 13
Urine output (mL)	9.44 ± 1.5	42.44 ± 5.1	37.44 ± 3.2	32.28 ± 4.3*	27 ± 3.6**	39.36 ± 4.8
Urine albumin (mg/dL)	4.02 ± 0.35	12.96 ± 1.03	11.06 ± 1.10	9.54 ± 1.03*	7.28 ± 0.63**	13.06 ± 1.04
Serum creatinine (mg/dL)	0.326 ± 0.03	1.406 ± 0.07	1.2 ± 0.12	1.016 ± 0.11*	0.776 ± 0.07**	1.352 ± 0.08
Blood urea nitrogen (mg/dL)	24.56 ± 1.48	61.16 ± 3.11	53.52 ± 3.03	49.18 ± 3.02*	43.84 ± 3.74**	63.46 ± 3.43

Note: The values are given as mean ± SD. *p < 0.01 and **p < 0.01 when compared with vehicle treated diabetic group.

Figure 1. Effects of 4-week treatment with MINO, ASP, and MINO in combination with ASP on creatinine clearance. The values are given as mean ± SD. *p < 0.05, **p < 0.01 when compared with vehicle treated control group.

Figure 2. Effects of 4-week treatment with MINO, ASP, and MINO in combination with ASP on renal hypertrophy. The values are given as mean ± SD. **p < 0.01 when compared with vehicle treated control group.

Figure 3. Effect of 4-week treatment with MINO, ASP, and MINO in combination with ASP on mean arterial pressure. The values are given as mean ± SD. *p < 0.05 when compared with vehicle treated diabetic group.

Table 2. Effects of 4-week treatment with MINO, ASP, and MINO in combination with ASP on renal artery collagen level and renal tubulointerstitial fibrosis index

Group	% Collagen	Tubulointerstitial fibrosis index
NORMO	26.9 ± 1.19	0
DB + DW	37.4 ± 2.73	1.6 ± 0.24
DB + MINO	35.2 ± 3.15	1.4 ± 0.24
DB + ASP	33.9 ± 2.87	1.0 ± 0.31
DB + ASP + MINO	30.8 ± 3.21*	0.6 ± 0.04*
DB + 0.5% CMC	38.1 ± 2.74	0

Note: The values are given as mean ± SD. *p < 0.01 when compared with vehicle treated diabetic group.

Figure 4. Effect of 4-week treatment with MINO, ASP, and MINO in combination with ASP on renal protein (72 kD) level. (a) Loading control; (b) DB + ASP + MINO; (c) DB + MINO; (d) DB + ASP; (e) DB + 0.5 % CMC; (f) DB + DW; (g) NORMO.

Figure 5. Effect of 4-week treatment with MINO, ASP, and MINO in combination with ASP on renal protein (92 kD) level. (a) Loading control; (b) DB + DW; (c) DB + MINO; (d) DB + ASP + MINO; (e) DB + ASP; (f) NORMO; (g) DB + 0.5% CMC.